Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Johanna HansenChristos A Kyratsous


Neutralizing antibodies have become an important tool in treating infectious diseases. Recently, two separate approaches yielded successful antibody treatments for Ebola-one from genetically humanized mice and the other from a human survivor. Here, we describe parallel efforts using both humanized mice and convalescent patients to generate antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, which yielded a large collection of fully human antibodies that were characterized for binding, neutralization, and three-dimensional structure. On the basis of these criteria, we selected pairs of highly potent individual antibodies that simultaneously bind the receptor binding domain of the spike protein, thereby providing ideal partners for a therapeutic antibody cocktail that aims to decrease the potential for virus escape mutants that might arise in response to selective pressure from a single-antibody treatment.


May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·N D LawsonJ K Rose
Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·A TakadaY Kawaoka
Nov 11, 1999·Journal of Molecular Recognition : JMR·D G Myszka
Oct 18, 2000·Journal of Immunological Methods·X Wang, B D Stollar
Jul 22, 2005·The Journal of General Virology·Shuetsu FukushiShigeru Morikawa
Dec 30, 2008·Analytical Biochemistry·Yasmina N AbdicheJaume Pons
Apr 8, 2014·Proceedings of the National Academy of Sciences of the United States of America·Andrew J MurphyGeorge D Yancopoulos
Apr 8, 2014·Proceedings of the National Academy of Sciences of the United States of America·Lynn E MacdonaldAndrew J Murphy
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jan 6, 2016·The Journal of Clinical Investigation·David J DiLilloJeffrey V Ravetch
Feb 7, 2017·Nature Methods·Ali PunjaniMarcus A Brubaker
Jun 4, 2018·The Journal of Infectious Diseases·Kristen E PascalChristos A Kyratsous
Aug 11, 2018·Cell·Erica Ollmann SaphireUNKNOWN Viral Hemorrhagic Fever Immunotherapeutic Consortium
Oct 20, 2018·Nature Immunology·Erica Ollmann SaphireGalit Alter
Feb 23, 2020·Science·Daniel WrappJason S McLellan
Mar 11, 2020·Cell·Alexandra C WallsDavid Veesler
Mar 25, 2020·Emerging Microbes & Infections·Jianhui NieYouchun Wang
Apr 18, 2020·Emerging Microbes & Infections·Siu-Ying LauHonglin Chen
Apr 26, 2020·Nature Communications·Changhai LeiShi Hu
Jun 9, 2020·BioRxiv : the Preprint Server for Biology·Thomas F RogersDennis R Burton

❮ Previous
Next ❯


Jun 28, 2020·Journal of Virology·John P Moore, P J Klasse
Sep 4, 2020·Signal Transduction and Targeted Therapy·Xiangyu ChenLilin Ye
Sep 30, 2020·Proceedings of the National Academy of Sciences of the United States of America·Mary Hongying ChengIvet Bahar
Jul 6, 2020·Nature·Gary R Whittaker, Susan Daniel
Sep 3, 2020·Vaccines·José M Pérez de la LastraAntonio Morales-delaNuez
Jul 29, 2020·International Journal of Molecular Sciences·Rami A Al-HoraniKholoud F Aliter
Aug 18, 2020·Bioinformatics·Matthew I J RaybouldCharlotte M Deane
Oct 29, 2020·ELife·Yiska WeisblumPaul D Bieniasz
Nov 25, 2020·Current Opinion in HIV and AIDS·Pilar MendozaChristian Gaebler
Nov 20, 2020·The Journal of Experimental Medicine·Alexandra SchäferTimothy P Sheahan
Oct 13, 2020·Nature·Christopher O BarnesPamela J Bjorkman
Dec 8, 2020·Annals of Internal Medicine·Ruanne V BarnabasUNKNOWN Hydroxychloroquine COVID-19 PEP Study Team
Dec 16, 2020·SLAS Discovery·Dawid MaciorowskiAdinarayana Kunamneni
Dec 16, 2020·MAbs·Marco TuccoriDaniele Focosi
Oct 21, 2020·Nature Reviews. Nephrology·Luca PericoGiuseppe Remuzzi
Dec 18, 2020·The New England Journal of Medicine·David M WeinreichUNKNOWN Trial Investigators
Nov 6, 2020·Transplantation·Yorg AzziEnver Akalin
Dec 23, 2020·Chembiochem : a European Journal of Chemical Biology·Kourosh Honarmand Ebrahimi
Jan 1, 2021·PloS One·Nathan PostSharif A Ismail
Nov 26, 2020·Computational and Structural Biotechnology Journal·Desh Deepak SinghDharmendra Kumar Yadav
Nov 18, 2020·Computational and Structural Biotechnology Journal·Masaud ShahHyun Goo Woo
Jan 14, 2021·Journal of Biomedical Science·Ioannis P TrougakosMeletios A Dimopoulos
Jan 14, 2021·The Biochemical Journal·George M Burslem
Oct 25, 2020·The Protein Journal·Mihaela Ileana Ionescu
Jan 8, 2021·Global Health & Medicine·Robert W Shafer
Nov 21, 2020·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Vladislav IzdaAmr H Sawalha
Dec 15, 2020·Advanced Drug Delivery Reviews·Carlos Cruz-TeranSamuel K Lai
Dec 15, 2020·Journal of Molecular Biology·Takamitsu HattoriShohei Koide
Jan 21, 2021·The New England Journal of Medicine·Myron S Cohen
Sep 30, 2020·Cytotherapy·Kuttuvan Valappil Sajna, Siya Kamat
Jan 25, 2021·International Immunopharmacology·Leila Mohamed KhosroshahiFarshid Noorbakhsh

❮ Previous
Next ❯

Methods Mentioned

enzyme-linked immunosorbent assay
fluorescence-activated single-cell sorting

Clinical Trials Mentioned


Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Related Papers

Methods : a Companion to Methods in Enzymology
Herren Wu, William F Dall'Acqua
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
S K Vaswani, R G Hamilton
© 2021 Meta ULC. All rights reserved